FBLG — Fibrobiologics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Fibrobiologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.58 | -5.12 | -16.5 | -11.2 | -18.6 |
| Depreciation | |||||
| Non-Cash Items | — | 0.748 | 9.54 | -1.46 | 5.32 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.172 | 0.307 | 0.493 | 0.559 | -3.31 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -1.41 | -4.07 | -6.4 | -11.9 | -16.4 |
| Capital Expenditures | — | — | -0.495 | -0.184 | -0.262 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | — | — | -0.495 | -0.184 | -0.262 |
| Financing Cash Flow Items | 0.292 | — | -2.65 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.82 | 5.92 | 13.8 | 16.9 | 7.57 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.407 | 1.86 | 6.9 | 4.82 | -9.09 |